المؤلفون: Dang, M. T., Chikkadi, V., Zargar, R., Miedema, D. M., Bonn, D., Zaccone, A., Schall, P.

مصطلحات موضوعية: Condensed Matter - Soft Condensed Matter

الوصول الحر: http://arxiv.org/abs/1505.06759Test

المؤلفون: Chikkadi, V., Miedema, D. M., Nienhuis, B., Schall, P.

مصطلحات موضوعية: Condensed Matter - Soft Condensed Matter

الوصول الحر: http://arxiv.org/abs/1401.2100Test

المؤلفون: de Wijn, A. S., Miedema, D. M., Nienhuis, B., Schall, P.

المصدر: Phys. Rev. Lett. 109, 228001 (2012)

مصطلحات موضوعية: Condensed Matter - Statistical Mechanics, Condensed Matter - Disordered Systems and Neural Networks

الوصول الحر: http://arxiv.org/abs/1205.6486Test

المؤلفون: Frankell, A. M., Dietzen, M., Al Bakir, M., Lim, E. L., Karasaki, T., Ward, S., Veeriah, S., Colliver, E., Huebner, A., Bunkum, A., Hill, M. S., Grigoriadis, K., Moore, D. A., Black, J. R. M., Liu, W. K., Thol, K., Pich, O., Watkins, T. B. K., Naceur-Lombardelli, C., Cook, D. E., Salgado, R., Wilson, G. A., Bailey, C., Angelova, M., Bentham, R., Martínez-Ruiz, C., Abbosh, C., Nicholson, A. G., Le Quesne, J., Biswas, D., Rosenthal, R., Puttick, C., Hessey, S., Lee, C., Prymas, P., Toncheva, A., Smith, J., Xing, W., Nicod, J., Price, G., Kerr, K. M., Naidu, B., Middleton, G., Blyth, K. G., Fennell, D. A., Forster, M. D., Lee, S. M., Falzon, M., Hewish, M., Shackcloth, M. J., Lim, E., Benafif, S., Russell, P., Boleti, E., Krebs, Matthew G, Lester, J. F., Papadatos-Pastos, D., Ahmad, T., Thakrar, R. M., Lawrence, D., Navani, N., Janes, S. M., Dive, Caroline, Blackhall, Fiona H, Summers, Yvonne J, Cave, J., Marafioti, T., Herrero, J., Quezada, S. A., Peggs, K. S., Schwarz, R. F., Van Loo, P., Miedema, D. M., Birkbak, N. J., Hiley, C. T., Hackshaw, A., Zaccaria, S., Jamal-Hanjani, M., McGranahan, N., Swanton, C.

المساهمون: Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK

العلاقة: https://dx.doi.org/10.1038/s41586-023-05783-5Test; Frankell AM, Dietzen M, Al Bakir M, Lim EL, Karasaki T, Ward S, et al. The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature. 2023 Apr;616(7957):525-33. PubMed PMID: 37046096. Pubmed Central PMCID: PMC10115649 for tumour monitoring (PCT/EP2022/077987). M.A.B. has consulted for Achilles Therapeutics. D.A.M. reports speaker fees from AstraZeneca, Eli Lilly and Takeda, consultancy fees from AstraZeneca, Thermo Fisher, Takeda, Amgen, Janssen, MIM Software, Bristol-Myers Squibb (BMS) and Eli Lilly and has received educational support from Takeda and Amgen. S.V. is a co-inventor on a patent to detect molecules in a sample (US patent 10578620). G.A.W. is employed by and has stock options in Achilles Therapeutics. R.S. reports non-financial support from Merck and BMS, research support from Merck, Puma Biotechnology and Roche, and personal fees from Roche, BMS and Exact Sciences for advisory boards. C.A. has received speaking honoraria or expenses from Novartis, Roche, AstraZeneca and BMS and reports employment at AstraZeneca. C.A. is an inventor on a European patent application relating to assay technology to detect tumour recurrence (PCT/GB2017/053289); the patent has been licensed to commercial entities and under their terms of employment, C.A. is due a revenue share of any revenue generated from such licence(s). C.A. declares a patent application (PCT/US2017/028013) for methods to detect lung cancer. C.A. is a named inventor on a patent application to determine methods and systems for tumour monitoring (PCT/EP2022/077987). C.A. is a named inventor on a provisional patent protection related to a ctDNA detection algorithm. D.B. reports personal fees from NanoString and AstraZeneca. He has a patent (PCT/GB2020/050221) issued on methods for cancer prognostication. R.R. is an employee of and has stock options in Achilles Therapeutics and holds a European patent on targeting neoantigens (PCT/EP2016/059401) and in determining HLA LOH (PCT/GB2018/052004). D.A.F. reports grants from Aldeyra, Boehringer Ingelheim, Astex Therapeutics, Bayer, BMS, GSK, RS Oncology, Clovis, Eli Lilly, MSD, GSK, personal fees from Atara, BMS, Boehringer Ingelheim, Cambridge Clinical Laboratories, Targovax, Roche and RS Oncology. M.D.F. acknowledges grant support from CRUK, AstraZeneca, Boehringer Ingelheim, MSD and Merck; is an advisory board member for Transgene; and has consulted for Achilles, Amgen, AstraZeneca, Bayer, Boxer, BMS, Celgene, EQRx, Guardant Health, Immutep, Ixogen, Janssen, Merck, MSD, Nanobiotix, Novartis, Oxford VacMedix, Pharmamar, Pfizer, Roche, Takeda and UltraHuman. K.S.P. is a co-founder of Achilles Therapeutics. S.A.Q. is a co-founder, stockholder and Chief Scientific Officer of Achilles Therapeutics. E.L. has received funding from AstraZeneca, Boehringer Ingelheim, Medela, Johnson & Johnson/Ethicon, Covidien/Medtronic, Guardant Health, Takeda, Lilly Oncology, Boehringer Ingelheim and Bayer. E.L. has received consulting fees from Beigene, Roche and BMS, honoraria from Medela and is a founder My Cancer Companion, Healthcare Companion Ltd. N.N. reports honoraria for non-promotional educational talks, advisory boards or conference attendance from Amgen, AstraZeneca, Boehringer Ingelheim, BMS, Fujifilm, Guardant Health, Intuitive, Janssen, Lilly, Merck Sharp & Dohme, Olympus, OncLive, PeerVoice, Pfizer and Takeda. S.M.J. has received fees for advisory board membership in the past 3 years from AstraZeneca, Bard1 Lifescience and Johnson & Johnson. He has received a grant income from Owlstone and GRAIL Inc. He has received assistance with travel to an academic meeting from Cheisi. C.D. has received research funding and educational research grants from AstraZeneca, Astex Pharmaceuticals, Bioven, Amgen, Carrick Therapeutics, Merck, Taiho Oncology, GSK, Bayer, Boehringer Ingelheim, Roche, BMS, Novartis, Celgene, Epigene Therapeutics, Angle PLC, Menarini, Clearbridge Biomedics, Thermo Fisher Scientific and Neomed Therapeutics. C.D. has also received honoraria for consultancy and/or advisory boards from Biocartis, Merck, AstraZeneca, GRAIL and Boehringer Ingelheim. J.C. reports funding from Amgen to attend a conference. A. Hackshaw has received fees for being a member of Independent Data Monitoring Committees for Roche-sponsored clinical trials, and academic projects co-ordinated by Roche. N.J.B. is a co-inventor on a patent to identify responders to cancer treatment (PCT/GB2018/051912), has a patent application (PCT/GB2020/050221) on methods for cancer prognostication and is a co-inventor on a patent for methods for predicting anticancer responses (US14/466,208). C.T.H. has received speaker fees from AstraZeneca. M.J.-H. has consulted for and is a member of the Achilles Therapeutics Scientific Advisory Board (SAB) and Steering Committee, has received speaker honoraria from Pfizer, Astex Pharmaceuticals, Oslo Cancer Cluster, and holds a patent (PCT/US2017/028013) relating to methods for lung cancer detection. This patent has been licensed to commercial entities and under terms of employment, M.J.-H. is due a share of any revenue generated from such licence(s). N.M. has received consultancy fees and has stock options in Achilles Therapeutics. N.M. holds European patents relating to targeting neoantigens (PCT/EP2016/059401), identifying patient response to immune checkpoint blockade (PCT/EP2016/071471), determining HLA LOH (PCT/GB2018/052004) and predicting survival rates of patients with cancer (PCT/GB2020/050221). C.S. acknowledges grant support from AstraZeneca, Boehringer-Ingelheim, BMS, Pfizer, Roche-Ventana, Invitae (previously Archer Dx (collaboration in minimal residual disease sequencing technologies)) and Ono Pharmaceutical. C.S. is an AstraZeneca Advisory Board member and Chief Investigator for the AZ MeRmaiD 1 and 2 clinical trials and is also Co-Chief Investigator of the NHS Galleri trial funded by GRAIL and a paid member of GRAIL’s SAB. He receives consultant fees from Achilles Therapeutics (also a SAB member), Bicycle Therapeutics (also a SAB member), Genentech, Medicxi, Roche Innovation Centre–Shanghai, Metabomed (until July 2022), and the Sarah Cannon Research Institute. C.S. had stock options in Apogen Biotechnologies and GRAIL until June 2021, and currently has stock options in Epic Bioscience, Bicycle Therapeutics, and has stock options and is co-founder of Achilles Therapeutics. C.S. is an inventor on a European patent application relating to an assay technology to detect tumour recurrence (PCT/GB2017/053289), the patent has been licensed to commercial entities and under his terms of employment, C.S. is due a revenue share of any revenue generated from such licence(s). C.S. holds patents relating to targeting neoantigens (PCT/EP2016/059401), identifying patient responses to immune checkpoint blockade (PCT/EP2016/071471), determining HLA LOH (PCT/GB2018/052004), predicting survival rates of patients with cancer (PCT/GB2020/050221), identifying patients who respond to cancer treatment (PCT/GB2018/051912), a US patent relating to detecting tumour mutations (PCT/US2017/28013), methods for lung cancer detection (US20190106751A1) and both a European and US patent related to identifying indel mutation targets (PCT/GB2018/051892) and is a co-inventor on a patent application to determine methods and systems for tumour monitoring (PCT/EP2022/077987). C.S. is a named inventor on a provisional patent related to a ctDNA detection algorithm. Epub 2023/04/13. eng.; http://hdl.handle.net/10541/626225Test; Nature

الإتاحة: https://doi.org/10.1038/s41586-023-05783-5Test
http://hdl.handle.net/10541/626225Test

المؤلفون: Lenos, K. J., Lodestijn, S. C., Lyons, S. K., Bijlsma, M. F., Miedema, D. M., Vermeulen, L.

مصطلحات موضوعية: cancer, cell lineage tracing

العلاقة: Lenos, K. J., Lodestijn, S. C., Lyons, S. K., Bijlsma, M. F., Miedema, D. M., Vermeulen, L. (August 2019) A marker-independent lineage-tracing system to quantify clonal dynamics and stem cell functionality in cancer tissue. Nat Protoc, 14 (9). pp. 2648-2671. ISSN 1750-2799

الإتاحة: https://doi.org/10.1038/s41596-019-0194-yTest
http://repository.cshl.edu/id/eprint/38288Test/
https://www.ncbi.nlm.nih.gov/pubmed/31420599Test

المؤلفون: Lenos, K. J., Miedema, D. M., Lodestijn, S. C., Nijman, L. E., van den Bosch, T., Romero Ros, X., Lourenco, F. C., Lecca, M. C., van der Heijden, M., van Neerven, S. M., van Oort, A., Leveille, N., Adam, R. S., de Sousa, E. Melo F., Otten, J., Veerman, P., Hypolite, G., Koens, L., Lyons, S. K., Stassi, G., Winton, D. J., Medema, J. P., Morrissey, E., Bijlsma, M. F., Vermeulen, L.

مصطلحات موضوعية: colon cancer, stem cells

العلاقة: Lenos, K. J., Miedema, D. M., Lodestijn, S. C., Nijman, L. E., van den Bosch, T., Romero Ros, X., Lourenco, F. C., Lecca, M. C., van der Heijden, M., van Neerven, S. M., van Oort, A., Leveille, N., Adam, R. S., de Sousa, E. Melo F., Otten, J., Veerman, P., Hypolite, G., Koens, L., Lyons, S. K., Stassi, G., Winton, D. J., Medema, J. P., Morrissey, E., Bijlsma, M. F., Vermeulen, L. (September 2018) Stem cell functionality is microenvironmentally defined during tumour expansion and therapy response in colon cancer. Nat Cell Biol, 20 (10). pp. 1193-1202. ISSN 1465-7392

الإتاحة: https://doi.org/10.1038/s41556-018-0179-zTest
http://repository.cshl.edu/id/eprint/37194Test/
https://www.ncbi.nlm.nih.gov/pubmed/30177776Test

المؤلفون: Denisov, D. V., Miedema, D. M., Nienhuis, B., Schall, P.

المساهمون: Nederlandse Organisatie voor Wetenschappelijk Onderzoek

المصدر: Physical Review E ; volume 92, issue 5 ; ISSN 1539-3755 1550-2376

مصطلحات موضوعية: General Medicine

الإتاحة: https://doi.org/10.1103/physreve.92.052714Test

المؤلفون: Miedema, D. M., de Wijn, A. S., Schall, P.

المصدر: Physical Review E ; volume 89, issue 6 ; ISSN 1539-3755 1550-2376

مصطلحات موضوعية: General Medicine

الإتاحة: https://doi.org/10.1103/physreve.89.062812Test

المؤلفون: Kushwaha, V. S., Miedema, D. M., Denisov, D. V., Acar, S., Nienhuis, B., Schall, P., Erwin Peterman

المساهمون: Physics of Living Systems, LaserLaB - Molecular Biophysics

المصدر: Vrije Universiteit Amsterdam
Kushwaha, V S, Miedema, D M, Denisov, D V, Acar, S, Nienhuis, B, Schall, P & Peterman, E J G 2016, ' How Kinesin Motor Proteins Deal with Traffic Jams ', Biophysical Journal, vol. 110, no. 3, pp. 462A-462A .
Biophysical Journal, 110(3), 462A-462A. Biophysical Society
CIÊNCIAVITAE

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::328fddc34071c51738e601a9933e6bb7Test
https://research.vu.nl/portal/en/publications/how-kinesin-motor-proteins-deal-with-traffic-jamsTest(75e315bb-49b8-42e7-b98f-e535adb2ba5c).html